The latest price target for RAPT Therapeutics (NASDAQ:RAPT) was reported by JP Morgan on November 12, 2025. The analyst firm set a price target for $57.00 expecting RAPT to rise to within 12 months (a possible 54.89% upside). 21 analyst firms have reported ratings in the last year.

The latest analyst rating for RAPT Therapeutics (NASDAQ:RAPT) was provided by JP Morgan, and RAPT Therapeutics maintained their overweight rating.

The last upgrade for RAPT Therapeutics Inc happened on October 20, 2025 when JP Morgan raised their price target to $55. JP Morgan previously had a neutral for RAPT Therapeutics Inc.

The last downgrade for RAPT Therapeutics Inc happened on November 11, 2024 when JP Morgan changed their price target from N/A to N/A for RAPT Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of RAPT Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for RAPT Therapeutics was filed on November 12, 2025 so you should expect the next rating to be made available sometime around November 12, 2026.

While ratings are subjective and will change, the latest RAPT Therapeutics (RAPT) rating was a maintained with a price target of $55.00 to $57.00. The current price RAPT Therapeutics (RAPT) is trading at is $36.80, which is out of the analyst’s predicted range.